AMD Clinical Trial
The purpose of this study is to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of dry age-related macular degeneration (AMD) in patients who are at-risk for progressing to wet AMD.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
| Recruiting |
NCT03893474 -
Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners
|
N/A | |
| Completed |
NCT00971464 -
Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation
|
Phase 2 | |
| Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
| Completed |
NCT01766596 -
Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)
|
N/A | |
| Completed |
NCT03322930 -
Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
|
||
| Completed |
NCT01778491 -
AMD Phenotype and Genotype Study
|
||
| Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
| Active, not recruiting |
NCT03845582 -
Phase 3 Study of ALK-001 in Geographic Atrophy
|
Phase 3 | |
| Completed |
NCT03367767 -
Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
|
||
| Completed |
NCT03372746 -
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
|
||
| Terminated |
NCT00333216 -
Anecortave Acetate Risk-Reduction Trial (AART)
|
Phase 3 | |
| Completed |
NCT01570790 -
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT00346866 -
Anecortave Acetate Versus Placebo in AMD Patients Following PDT
|
Phase 2 | |
| Withdrawn |
NCT00726466 -
Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
|
Phase 1 | |
| Completed |
NCT00306488 -
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
|
Phase 2 | |
| Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT01632527 -
Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A | |
| Recruiting |
NCT03675880 -
TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects
|
Phase 1 |